"Designing Growth Strategies is in our DNA"

Middle East & Africa Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030

Last Updated: April 28, 2025 | Format: PDF | Report ID: FBI107919

 

Middle East & Africa Multiple Sclerosis Drugs Market

Request Now
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Multiple Sclerosis - For Key Countries
    2. Patent Snapshot, Key Players
    3. Pipeline Analysis & R&D Investments
    4. Key Industry Developments (Mergers, Acquisitions, Partnerships; etc.)
    5. Impact of COVID-19 on the Market
  5. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. South Africa
      2. GCC
      3. Rest of Middle East & Africa
  6. Competitive Analysis
    1. Middle East & Africa Market Share Analysis
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Biogen
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. Teva Pharmaceutical Industries Ltd.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. Merck KGaA
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. Sanofi
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Novartis AG
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      6. F. Hoffmann-La Roche Ltd.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      7. Pfizer Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      9. Bristol-Myers Squibb Company
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
Read Less

Figure 1:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue Breakdown (USD Billion, %) by Country/Sub-region, 2022 & 2030

Figure 2:  Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2022 & 2030

Figure 3:  Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2022 & 2030

Figure 4:  Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 5:  Middle East & Africa Multiple Sclerosis Drugs Market Value (USD Billion), By Country/ Sub-region, 2022 & 2030

Figure 6:  Middle East & Africa Multiple Sclerosis Drugs Market Share (%), By Company

Table 1:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Drug Class, 2019–2030

Table 2:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Route of Administration, 2019–2030

Table 3:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Injection, 2019–2030

Table 4:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Distribution Channel, 2019–2030

Table 5:  Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Country/Sub-region, 2019–2030

Middle East & Africa Multiple Sclerosis Drugs Market Size, Share and Global Industry Trend Forecast till 2030
  • 2019-2030
  • 2022
  • 2019-2021
  • 109
GET A FREE SAMPLE
    The free sample includes data points such as market estimates, growth rate, size of the largest region and segment of the market.
Consulting Services
    How will you benefit from our consulting services ?